Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice

Abstract

BackgroundAlzheimer’s disease is widely described since the discovery of histopathological lesions in Mrs. Auguste Deter in 1906. However to date, there is no effective treatment to deal with the many cellular and molecular alterations. The complexity is even higher with the growing evidence of involvement of the peripheral blood mononuclear cells (PBMCs). Indeed, monocytes and T cells are shown in the cerebral parenchyma of AD patients, and these cells grafted to the periphery are able to go through the blood-brain barrier (BBB) in transgenic mouse models. It is known that BBB is disrupted at a late stage of AD. Chemokines represent major regulators of the transmigration of PBMCs, but many data were obtained on AD animal models. No data are available on the role of AD BBB in a healthy brain parenchyma. Therefore, the purpose of this study was to analyze the longitudinal chemokine profile expression in a BBB model from AD transgenic mice versus wild-type (WT) mice.MethodsA primary mouse BBB model was used with a luminal compartment either AD or WT and an abluminal compartment WT consisting of astrocytes and microglia. PBMCs were extracted by a ficoll gradient and incubated in the transwell with a direct contact with the luminal side, including the endothelial cells and pericytes. Then, the complete BBB model was incubated during 48 h, before supernatants and cell lysates were collected. Chemokines were quantified by X-MAP® luminex technology.ResultsAbluminal CX3CL1 production increased in 12-month-old AD BBB while CX3CL1 levels decreased in luminal lysates. CCL3 in luminal compartment increased with aging and was significantly different compared to AD BBB at 12 months. In addition, abluminal CCL2 in 12-month-old AD BBB greatly decreased compared to levels in WT BBB. On the contrary, no modification was observed for CCL4, CCL5, and CXCL10.ConclusionThese first findings highlighted the impact of AD luminal compartment on chemokine signature in a healthy brain parenchyma, suggesting new therapeutic or diagnostic approaches.Electronic supplementary materialThe online version of this article (10.1186/s12974-018-1220-7) contains supplementary material, which is available to authorized users.

<p>Transcriptome profiling of dorsal root ganglia in a rat model of complex regional pain syndrome type-I reveals potential mechanisms involved in pain</p>

“…KEGG analysis shows that most of the upregulated genes are involved in phagosome. We noticed that phagosome was also observed in another study investigating DEGs in spinal dorsal horn involved in CCI-induced neuropathic pain model 21. One of the genes involved in phagosome is Itgam , which is a marker for macrophage.…”

<p>Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma</p>

“…These results would confirm that the expression of PD-L1 is, at least in part, regulated by the GDF15/Smad2/3 signaling pathway in GBMs. Some reports indicated that Interferon-related signaling pathway could enhance PD-L1 expression in glioma 43,44. However, we did not observe the correlated expression between IFNγ and GDF15, suggesting GDF15 effect on PD-L1 might be independent of Interferon signaling in GBM.…”

Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection?

“…Dysfunction of astrocytes causes glutamate accumulation with ensuing excitotoxicity ( Werner et al, 2001 ). Reactive astrocytes can further precipitate neuroinflammation ( Verite et al, 2018 ) through the release of pro-inflammatory cytokines and chemokines, including CCL2, which recruits peripheral monocytes into the CNS. Accordingly, apoptotic astrocytes and reactive astrogliosis critically contribute to neurodegenerative processes in different forms of dementia ( Heneka et al, 2010 ) including AD ( Kobayashi et al, 2002 ), vascular ( Tomimoto et al, 1997 ), and frontotemporal dementia ( Martin, 2000 ).…”